Vaccine

Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product CandidatesEmergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates

Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates

GAITHERSBURG, Md. and BASEL, Switzerland, March 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS), a leading public health…

4 months ago
Bavarian Nordic A/S – Notice Convening Annual General MeetingBavarian Nordic A/S – Notice Convening Annual General Meeting

Bavarian Nordic A/S – Notice Convening Annual General Meeting

COPENHAGEN, Denmark, March 12, 2025 – Pursuant to Articles 10-14 of the Articles of Association, the shareholders of Bavarian Nordic…

4 months ago
AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand ConferenceAIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

On-demand video webcast now available Includes latest updates on pancreatic cancer and bird flu clinical trials OCALA, Fla., March 11,…

4 months ago
Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine CandidateVaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate

Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate

- Topline data expected as early as mid-2025 - SOUTH SAN FRANCISCO, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Vaxart,…

4 months ago
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General HospitalAlzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital

Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure…

4 months ago
Tonix Pharmaceuticals to Present at the Zacks SCR Life Sciences Virtual Investor Forum on March 13thTonix Pharmaceuticals to Present at the Zacks SCR Life Sciences Virtual Investor Forum on March 13th

Tonix Pharmaceuticals to Present at the Zacks SCR Life Sciences Virtual Investor Forum on March 13th

CHATHAM, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biopharmaceutical company with marketed…

4 months ago
Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AADDupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD

Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also…

4 months ago
Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AADPress Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease…

4 months ago
Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock MarketVaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market

Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market

ROCHESTER, N.Y., March 07, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTC: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company…

4 months ago
Cure© Hosts Power of X Summit to Drive Investment and Solutions in Untapped Trillion-Dollar Market Addressing Health of WomenCure© Hosts Power of X Summit to Drive Investment and Solutions in Untapped Trillion-Dollar Market Addressing Health of Women

Cure© Hosts Power of X Summit to Drive Investment and Solutions in Untapped Trillion-Dollar Market Addressing Health of Women

Event's Impact Challenge to Award One Early-Stage Company Up to $100K for Innovative Women's Health Solutions NEW YORK, March 6,…

4 months ago